<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365091</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-162</org_study_id>
    <nct_id>NCT01365091</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil</brief_title>
  <official_title>Bioequivalence Study of Fixed Dose Combinations of Saxagliptin/Metformin Extended Release (XR) Relative to Co-administration of the Individual Components in Healthy Subjects in the Fasted and Fed States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the bioequivalence of saxagliptin and metformin in a saxagliptin,
      5-mg/metformin extended-release (XR), 500-mg, fixed-dose combination (FDC) tablet with
      saxagliptin, 5-mg and metformin, 500-mg XR tablets administered together in both the fasted
      and fed states. In addition, to demonstrate the bioequivalence of saxagliptin and metformin
      in a saxagliptin, 5-mg/metformin XR, 1000-mg, FDC tablet with saxagliptin, 5-mg and
      metformin, 1000-mg XR tablets administered together in both the fasted and fed states.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets</measure>
    <time_frame>Days 1, 2, and 3 of Periods 1 and 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets</measure>
    <time_frame>Days 1, 2, and 3 of Periods 1 and 2</time_frame>
    <description>AUC=Area under the concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets</measure>
    <time_frame>Days 1, 2, and 3 of Periods 1 and 2</time_frame>
    <description>AUC=Area Under the Concentration-time Curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death as Outcome and Serious Adverse Events (SAEs)</measure>
    <time_frame>Continuously, from screening through Day 1 to within 30 days of drug discontinuation on Day 1</time_frame>
    <description>SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Arm 1: Treatments A,B/B,A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Treatments C,D/D,C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Treatments E, F/F,E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Treatments G,H/H,G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin/metformin fixed-dose combination (FDC)</intervention_name>
    <description>Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day</description>
    <arm_group_label>Arm 1: Treatments A,B/B,A</arm_group_label>
    <arm_group_label>Arm 2: Treatments C,D/D,C</arm_group_label>
    <other_name>Onglyza/Glucophage extended release (XR)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Tablet, oral, 5 mg, once on Day 1 only, 1 day</description>
    <arm_group_label>Arm 1: Treatments A,B/B,A</arm_group_label>
    <arm_group_label>Arm 2: Treatments C,D/D,C</arm_group_label>
    <arm_group_label>Arm 3: Treatments E, F/F,E</arm_group_label>
    <arm_group_label>Arm 4: Treatments G,H/H,G</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin extended-release (XR)</intervention_name>
    <description>Tablet, oral, 500 mg, once on Day 1 only, 1 day</description>
    <arm_group_label>Arm 1: Treatments A,B/B,A</arm_group_label>
    <arm_group_label>Arm 2: Treatments C,D/D,C</arm_group_label>
    <other_name>Glifage XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin/Metformin FDC</intervention_name>
    <description>Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day</description>
    <arm_group_label>Arm 3: Treatments E, F/F,E</arm_group_label>
    <arm_group_label>Arm 4: Treatments G,H/H,G</arm_group_label>
    <other_name>Onglyza/Glucophage XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Tablet, oral, 1000 mg, once on Day 1 only, 1 day</description>
    <arm_group_label>Arm 3: Treatments E, F/F,E</arm_group_label>
    <arm_group_label>Arm 4: Treatments G,H/H,G</arm_group_label>
    <other_name>Glifage XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy men and women

          -  women of childbearing potential who are using acceptable method of contraception

          -  Women who are not pregnant or nursing

          -  Body Mass Index (BMI) of 18 to 29.9 kg/m^2, inclusive. BMI=weight(kg)/height(m)^2.

        Key Exclusion Criteria:

          -  Any significant acute or chronic medical illness.

          -  History of gastrointestinal (GI) disease

          -  Major surgery within 4 weeks of study drug administration

          -  Any GI surgery that could impact study drug absorption

          -  Donation of blood or plasma to a blood bank or in a clinical study (except a screening
             visit) within the 6 months of study drug administration.

          -  Blood transfusion within 3 months of study drug administration for women and within 2
             months for men

          -  Inability to be venipunctured and/or tolerate venous access

          -  Current smoker or recent (within 1 month) history of regular tobacco use

          -  Recent (within 6 months of study drug administration) drug or alcohol abuse

          -  Participation in a bioequivalence study within the last 6 months of study drug
             administration

          -  Estimated creatinine clearance of &lt;80 mL/min using Cockcroft-Gault formula

          -  History of allergy to drug class or related compounds

          -  History of allergy to metformin or other similar acting agents

          -  History of any significant drug allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13073</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <results_first_submitted>March 20, 2013</results_first_submitted>
  <results_first_submitted_qc>August 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2013</results_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Treatments A/B, B/A</title>
          <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A).</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Treatments C/D, D/C</title>
          <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C).</description>
        </group>
        <group group_id="P3">
          <title>Arm 3:Treatments E/ F, F/E</title>
          <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E).</description>
        </group>
        <group group_id="P4">
          <title>Arm 4: Treatments G/ H, H/G</title>
          <description>Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive test result for drugs of abuse</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer met study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Treatments A/B, B/A</title>
          <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A).</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Treatments C/D, D/C</title>
          <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C).</description>
        </group>
        <group group_id="B3">
          <title>Arm 3:Treatments E/ F, F/E</title>
          <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E).</description>
        </group>
        <group group_id="B4">
          <title>Arm 4: Treatments G/ H, H/G</title>
          <description>Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>The clinical study report (CSR) stated only that participants of both genders were enrolled. The CSR did not report the number of each gender enrolled.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Both genders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets</title>
        <time_frame>Days 1, 2, and 3 of Periods 1 and 2</time_frame>
        <population>Participants who received study medication and were evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Sax, 5 mg/Met 500 mg XR FDC vs Individual Tablets, Fasted</title>
            <description>Arm 1: Treatments A, B/B, A. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 500-mg extended-release (XR) fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500-mg FDC, in the fasted state (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Sax, 5 mg/Met 500 mg vs FDC to Individual Tablets, Fed</title>
            <description>Arm 2: Treatment C, D/D, C. Period 1: Participants received a single oral dose of saxagliptin (sax) 5-mg/metformin (met) 500-mg, extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 500-mg XR FDC, in the fed state (Treatment C).</description>
          </group>
          <group group_id="O3">
            <title>Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted</title>
            <description>Arm 3: Treatment E, F/F, G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 1000-mg tablets, together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fasted state (Treatment E).</description>
          </group>
          <group group_id="O4">
            <title>Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed</title>
            <description>Arm 4: Treatments G,H/H,G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fed state (Treatment G).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets</title>
          <population>Participants who received study medication and were evaluable</population>
          <units>Î¼g/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Metformin Cmax (individual tablet)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="713" spread="176" lower_limit="87.618" upper_limit="103.446"/>
                    <measurement group_id="O2" value="654" spread="118" lower_limit="82.368" upper_limit="94.419"/>
                    <measurement group_id="O3" value="1177" spread="399" lower_limit="90.376" upper_limit="105.404"/>
                    <measurement group_id="O4" value="1077" spread="139" lower_limit="95.164" upper_limit="105.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin Cmax (FDC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="678" spread="167"/>
                    <measurement group_id="O2" value="577" spread="95"/>
                    <measurement group_id="O3" value="1139" spread="325"/>
                    <measurement group_id="O4" value="1091" spread="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saxagliptin Cmax (individual tablet)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29274" spread="10209" lower_limit="96.552" upper_limit="119.924"/>
                    <measurement group_id="O2" value="28339" spread="7339" lower_limit="92.263" upper_limit="104.451"/>
                    <measurement group_id="O3" value="30914" spread="7965" lower_limit="96.956" upper_limit="109.407"/>
                    <measurement group_id="O4" value="31319" spread="6270" lower_limit="89.055" upper_limit="98.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saxagliptin Cmax (FDC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31372" spread="11367"/>
                    <measurement group_id="O2" value="28140" spread="8311"/>
                    <measurement group_id="O3" value="33549" spread="7813"/>
                    <measurement group_id="O4" value="29545" spread="6006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-OH Saxagliptin Cmax (individual tablets)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54709" spread="16816" lower_limit="96.504" upper_limit="112.883"/>
                    <measurement group_id="O2" value="52628" spread="12850" lower_limit="91.470" upper_limit="98.714"/>
                    <measurement group_id="O3" value="56444" spread="14731" lower_limit="96.589" upper_limit="108.52"/>
                    <measurement group_id="O4" value="55177" spread="13751" lower_limit="95.572" upper_limit="103.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-OH Saxagliptin Cmax (FDC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56413" spread="15775"/>
                    <measurement group_id="O2" value="11316" spread="45404"/>
                    <measurement group_id="O3" value="59878" spread="15959"/>
                    <measurement group_id="O4" value="54521" spread="12319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Metformin, Arm 1: The corresponding power and coefficient of variation between test and reference drugs are 98% and 17.24%, respectively</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>95.204</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.618</ci_lower_limit>
            <ci_upper_limit>103.446</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 1: The corresponding power and coefficient of variation are 80% and 22.62%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>107.606</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.552</ci_lower_limit>
            <ci_upper_limit>119.924</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>5-OH Saxagliptin, Arm 1: The corresponding power and the coefficient of variation are 99% and 16.26%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>104.373</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.504</ci_lower_limit>
            <ci_upper_limit>112.883</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B= FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Metformin, Arm 2: The corresponding power and the variation coefficient are 81% and 14.42%,respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>88.188</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.368</ci_lower_limit>
            <ci_upper_limit>94.419</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 2: The corresponding power and the variation coefficient are 99% and 13.09%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.168</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.263</ci_lower_limit>
            <ci_upper_limit>104.451</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>5-OH saxagliptin, Arm 2: The corresponding power and the variation coefficient are 99% and 8.02%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>95.023</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.470</ci_lower_limit>
            <ci_upper_limit>98.714</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Metformin, Arm 3: The corresponding power and the variation coefficient are 99% and 15.55%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>97.601</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.55</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 3: The corresponding power and the variation coefficient are 84% and 15.65%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>110.656</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>102.416</ci_lower_limit>
            <ci_upper_limit>119.559</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>OH-Saxagliptin, Arm 3: The corresponding power and the variation coefficient are 99% and 12.61%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>106.264</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.826</ci_lower_limit>
            <ci_upper_limit>113.117</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Metformin, Arm 4: The corresponding power and the variation coefficient are 99% and 10.30%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>100.028</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.164</ci_lower_limit>
            <ci_upper_limit>105.139</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 4: The corresponding power and the variation coefficient are 99% and 10.38%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>93.644</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.055</ci_lower_limit>
            <ci_upper_limit>98.470</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets</title>
        <description>AUC=Area under the concentration-time curve</description>
        <time_frame>Days 1, 2, and 3 of Periods 1 and 2</time_frame>
        <population>Participants who received study medication and were evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met, 500 mg FDC Fasting</title>
            <description>Arm 1: Treatments A, B/B, A. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 500-mg extended-release (XR) fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500-mg FDC, in the fasted state (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met 500 mg FDC Fed</title>
            <description>Arm 2: Treatment C, D/D, C. Period 1: Participants received a single oral dose of saxagliptin (sax) 5-mg/metformin (met) 500-mg, extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 500-mg XR FDC, in the fed state (Treatment C).</description>
          </group>
          <group group_id="O3">
            <title>Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fasting</title>
            <description>Arm 3: Treatment E, F/F, G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 1000-mg tablets, together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fasted state (Treatment E).</description>
          </group>
          <group group_id="O4">
            <title>Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fed</title>
            <description>Arm 4: Treatments G,H/H,G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fed state (Treatment G).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets</title>
          <description>AUC=Area under the concentration-time curve</description>
          <population>Participants who received study medication and were evaluable</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Metformin AUC(0-T) (individual tablets)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5816" spread="1859" lower_limit="82.596" upper_limit="101.380"/>
                    <measurement group_id="O2" value="5071" spread="821" lower_limit="85.560" upper_limit="98.035"/>
                    <measurement group_id="O3" value="8174" spread="2394" lower_limit="96.956" upper_limit="109.407"/>
                    <measurement group_id="O4" value="9628" spread="3270" lower_limit="85.502" upper_limit="101.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin AUC(0-T) (FDC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5386" spread="1896"/>
                    <measurement group_id="O2" value="4701" spread="1028"/>
                    <measurement group_id="O3" value="8500" spread="2713"/>
                    <measurement group_id="O4" value="8936" spread="2696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saxagliptin AUC(0-T) (individual tablets)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106070" spread="26733"/>
                    <measurement group_id="O2" value="110285" spread="22139"/>
                    <measurement group_id="O3" value="102913" spread="22067"/>
                    <measurement group_id="O4" value="124536" spread="24794" lower_limit="98.494" upper_limit="104.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saxagliptin AUC(0-T) (FDC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103865" spread="31088"/>
                    <measurement group_id="O2" value="109345" spread="23947"/>
                    <measurement group_id="O3" value="99215" spread="20146"/>
                    <measurement group_id="O4" value="127232" spread="28709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-OH Saxagliptin AUC(0-T) (individual tablets)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320743" spread="68176"/>
                    <measurement group_id="O2" value="305354" spread="53254"/>
                    <measurement group_id="O3" value="324163" spread="59358"/>
                    <measurement group_id="O4" value="9628" spread="3270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-OH Saxagliptin AUC(0-T) (FDC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331332" spread="67491"/>
                    <measurement group_id="O2" value="292515" spread="45404"/>
                    <measurement group_id="O3" value="323039" spread="56031" lower_limit="96.512" upper_limit="103.648"/>
                    <measurement group_id="O4" value="8936" spread="2696" lower_limit="97.367" upper_limit="102.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Metformin, Arm 1: The corresponding power and coefficient of variation are 98% and 17.24%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>91.508</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.596</ci_lower_limit>
            <ci_upper_limit>101.380</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 1: The corresponding power and the coefficient of variation are 99% and 07.66%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>97.437</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.889</ci_lower_limit>
            <ci_upper_limit>101.119</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>5-OH Saxagliptin, Arm 1: The corresponding power and the coefficient of variation are 99% and 07.43%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>96.770</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.350</ci_lower_limit>
            <ci_upper_limit>100.316</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Metformin, Arm 2: The corresponding power and the variation coefficient are 96% and 14.37%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>91.585</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.56</ci_lower_limit>
            <ci_upper_limit>98.035</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 2: The corresponding power and the variation coefficient are 96.028% and 101.095%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.529</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.028</ci_lower_limit>
            <ci_upper_limit>101.095</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>5-OH Saxagliptin, Arm 2: The corresponding power and the variation coefficient are 99% and 6.55%, respectively</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>96.239</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.286</ci_lower_limit>
            <ci_upper_limit>99.286</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Metformin, Arm 3: The corresponding power and the variation coefficient are 99% and 12.19%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.994</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.956</ci_lower_limit>
            <ci_upper_limit>109.407</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 3: The corresponding power and the variation coefficient are 99% and 7.07%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>97.135</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.778</ci_lower_limit>
            <ci_upper_limit>100.613</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>5-OH Saxagliptin, Arm 3: The corresponding power and the variation coefficient are 99% and 7.18%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>100.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.512</ci_lower_limit>
            <ci_upper_limit>103.648</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Metformin, Arm 1:The corresponding power and the variation coefficient are 93% and 17.35%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>92.953</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.502</ci_lower_limit>
            <ci_upper_limit>101.053</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 4: The corresponding power and the variation coefficient are 99% and 5.75%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>101.281</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.494</ci_lower_limit>
            <ci_upper_limit>104.147</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>5-OH Saxagliptin, Arm 4: The corresponding power and the variation coefficient are 99% and 5.73%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>100.111</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.367</ci_lower_limit>
            <ci_upper_limit>102.932</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death as Outcome and Serious Adverse Events (SAEs)</title>
        <description>SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
        <time_frame>Continuously, from screening through Day 1 to within 30 days of drug discontinuation on Day 1</time_frame>
        <population>All enrolled participants who receive study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Treatments A,B/B,A</title>
            <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Treatments C,D/D,C</title>
            <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C).</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Treatments E,F/ F,E</title>
            <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E).</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: Treatments G,H/H,G</title>
            <description>Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death as Outcome and Serious Adverse Events (SAEs)</title>
          <description>SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
          <population>All enrolled participants who receive study medication</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets</title>
        <description>AUC=Area Under the Concentration-time Curve</description>
        <time_frame>Days 1, 2, and 3 of Periods 1 and 2</time_frame>
        <population>Participants who received study medication and were evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fasted</title>
            <description>Arm 1: Treatments A, B/B, A. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 500-mg extended-release (XR) fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500-mg FDC, in the fasted state (Treatment A).</description>
          </group>
          <group group_id="O2">
            <title>Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fed</title>
            <description>Arm 2: Treatment C, D/D, C. Period 1: Participants received a single oral dose of saxagliptin (sax) 5-mg/metformin (met) 500-mg, extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 500-mg XR FDC, in the fed state (Treatment C).</description>
          </group>
          <group group_id="O3">
            <title>Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted</title>
            <description>Arm 3: Treatment E, F/F, G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 1000-mg tablets, together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.
Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fasted state (Treatment E).</description>
          </group>
          <group group_id="O4">
            <title>Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed</title>
            <description>Arm 4: Treatments G,H/H,G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.
Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fed state (Treatment G).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets</title>
          <description>AUC=Area Under the Concentration-time Curve</description>
          <population>Participants who received study medication and were evaluable</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Metformin AUC (0-inf) (individual tablets)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5877" spread="1858"/>
                    <measurement group_id="O2" value="5127" spread="816"/>
                    <measurement group_id="O3" value="8338" spread="2414"/>
                    <measurement group_id="O4" value="9731" spread="3277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin AUC (0-inf) (FDC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5443" spread="1905" lower_limit="82.697" upper_limit="101.226"/>
                    <measurement group_id="O2" value="4754" spread="1037" lower_limit="85.573" upper_limit="97.939"/>
                    <measurement group_id="O3" value="8618" spread="2726" lower_limit="96.589" upper_limit="108.525"/>
                    <measurement group_id="O4" value="9054" spread="2684" lower_limit="85.835" upper_limit="101.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saxagliptin AUC (0-inf) (individual tablets)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107425" spread="26828" lower_limit="93.955" upper_limit="101.132"/>
                    <measurement group_id="O2" value="111677" spread="22315" lower_limit="96.044" upper_limit="101.090"/>
                    <measurement group_id="O3" value="104293" spread="22149" lower_limit="93.832" upper_limit="100.662"/>
                    <measurement group_id="O4" value="125820" spread="24856" lower_limit="98.574" upper_limit="104.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saxagliptin AUC (0-inf) (FDC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105248" spread="31314"/>
                    <measurement group_id="O2" value="110705" spread="24091"/>
                    <measurement group_id="O3" value="100620" spread="20264"/>
                    <measurement group_id="O4" value="128602" spread="28729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-OH Saxagliptin AUC (0-inf) (individual tablets)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337345" spread="67941" lower_limit="93.393" upper_limit="100.247"/>
                    <measurement group_id="O2" value="310983" spread="53447" lower_limit="93.319" upper_limit="99.290"/>
                    <measurement group_id="O3" value="330247" spread="59863" lower_limit="96.560" upper_limit="103.594"/>
                    <measurement group_id="O4" value="332495" spread="62192" lower_limit="97.324" upper_limit="102.864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-OH Saxagliptin AUC (0-inf) (FDC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326501" spread="68475"/>
                    <measurement group_id="O2" value="298037" spread="45636"/>
                    <measurement group_id="O3" value="329085" spread="56298"/>
                    <measurement group_id="O4" value="332869" spread="59469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For AUC(0-inf) metformin, Arm 1, the corresponding power and coefficient of variation are 80% and 21.06%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>91.494</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.697</ci_lower_limit>
            <ci_upper_limit>101.226</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 1: The corresponding power and the coefficient of variation are 99% and 07.60%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>97.477</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.955</ci_lower_limit>
            <ci_upper_limit>101.132</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>5-OH Saxagliptin, Arm 1. The corresponding power and the coefficient of variation are 99% and 07.31%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>96.760</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.393</ci_lower_limit>
            <ci_upper_limit>100.247</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Metformin, Arm 2: The corresponding power and the variation coefficient are 96% and 14.25%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>91.548</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.573</ci_lower_limit>
            <ci_upper_limit>97.939</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 2: The corresponding power and the variation coefficient are 99% and 5.38%,respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.535</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.044</ci_lower_limit>
            <ci_upper_limit>101.090</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>5-OH Saxagliptin, Arm 2: The corresponding power and the variation coefficient are 99% and 6.52%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>96.258</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.319</ci_lower_limit>
            <ci_upper_limit>99.290</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Metformin, Arm 3: The corresponding power and the variation coefficient are 99% and 11.75%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.383</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.589</ci_lower_limit>
            <ci_upper_limit>108.525</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 5: The corresponding power and the variation coefficient are 99% and 7.07%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>97.187</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.832</ci_lower_limit>
            <ci_upper_limit>100.662</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>5-OH Sarexagliptin, Arm 3: The corresponding power and the variation coefficient are 99% and 7.08%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>100.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.560</ci_lower_limit>
            <ci_upper_limit>103.594</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Metformin, Arm 4: The corresponding power and the variation coefficient are 94% and 17.13%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>93.219</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.835</ci_lower_limit>
            <ci_upper_limit>101.238</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Saxagliptin, Arm 4: The corresponding power and the variation coefficient are 99% and 5.72%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>101.346</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.574</ci_lower_limit>
            <ci_upper_limit>104.196</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>5-OH Saxagliptin, Arm 4: The corresponding power and the variation coefficient are 99% and 5.71%, respectively.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>100.056</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.324</ci_lower_limit>
            <ci_upper_limit>102.864</ci_upper_limit>
            <estimate_desc>Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening through Day 1 to within 30 days of drug discontinuation on Day 1</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Saxagliptin, 5 mg/Metformin XR, 1000 mg Fasting</title>
          <description>XR=extended release</description>
        </group>
        <group group_id="E2">
          <title>Saxagliptin, 5 mg/Metformin XR, 1000 mg Fed</title>
          <description>XR=extended release</description>
        </group>
        <group group_id="E3">
          <title>Saxagliptin, 5 mg/Metformin XR, 500 mg Fasting</title>
          <description>XR=extended release</description>
        </group>
        <group group_id="E4">
          <title>Saxagliptin, 5 mg/Metformin XR, 500 mg Fed</title>
          <description>XR=extended release</description>
        </group>
        <group group_id="E5">
          <title>Saxagliptin, 5 mg/Metformin, 1000 mg FDC Fasting</title>
          <description>FDC=fixed-dose combination</description>
        </group>
        <group group_id="E6">
          <title>Saxagliptin, 5 mg/Metformin, 1000 mg FDC Fed</title>
          <description>FDC=fixed-dose combination</description>
        </group>
        <group group_id="E7">
          <title>Saxagliptin, 5 mg/Metformin, 500 mg FDC Fasting</title>
          <description>FDC=fixed-dose combination</description>
        </group>
        <group group_id="E8">
          <title>Saxagliptin, 5 mg/Metformin, 500 mg FDC Fed</title>
          <description>FDC=fixed-dose combination</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>White blood cell disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Red blood cell abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Aptyalism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period â¤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boaz Hirschberg</name_or_title>
      <organization>AstraZeneca Pharmaceuticals</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

